Orgenesis Led Consortium Awarded €4M European Innovation Council Pathfinder Grant

GERMANTOWN, Md., May 03, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announces a consortium led by one of its subsidiaries, MIDA Biotech, has been approved to receive a grant of €4 million, under the European Innovation Council Pathfinder Challenge Program, supporting cutting-edge science and technology in order to create new market opportunities. The grant is aimed at the development of technologies enabling production of autologous induced pluripotent stem cells (iPSCs) using microfluidic technologies and artificial intelligence (AI). The technologies are expected to speed production of personalized iPSCs, while significantly reducing manufacturing cost. The consortium members include MIDA Biotech B.V. (“MIDA”), DeepMed IO, and Leiden University, with MIDA acting as the leading entity.